NPM1 and acute myeloid leukemia: FLT3ITD represents one of the most frequent genetic alterations with a 20% frequency in adult AML, 28–34% in cytogenetically normal AML [23], and 39% in NPM1-mutated AML [18]. FLT3ITD activates STAT5 to maintain survival of leukemic stem cell population in AML [24].